Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020
Taking into account the current COVID-19 situation, the Commission confirms that the listed FAQs, related to the management of Horizon 2020 grants under the crisis situation, continue being applicable, as listed on this page.
Source: Funding and tender portal
2024-02-15
|
1 month ago |
Horizon 2020 final evaluation |
2023-10-09
|
5 months ago |
Last few days to respond to survey: help us further improve NCP Flanders services |
2023-09-27
|
6 months ago |
NCP Flanders survey still open until 13 October |
2023-08-21
|
7 months ago |
NCP Flanders survey: looking for your feedback |
2023-06-26
|
9 months ago |
Call for applications for members of the European Commission expert group on Horizon... |
2023-06-09
|
9 months ago |
COM 2022 Report on Research and Technological Development Activities |
2022-12-02
|
1 year ago |
Public consultation: European research and innovation programmes 2014-2027 |
2022-07-07
|
1 year ago |
Horizon 2020 & Horizon Europe final and interim evaluations |
We offer news and event updates, covering all domains and topics of Horizon 2020 & Horizon Europe.
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.